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Abstract Interaction of advanced glycation end products
(AGE) with AGE receptors induces several cellular phenomena
potentially relating to diabetic complications. We here show
that AGE-modi¢ed bovine serum albumin (BSA) is endocytosed
by adipocytes via CD36. Upon di¡erentiation, 3T3-L1 and hu-
man subcutaneous adipose cells showed marked increases in
endocytic uptake and subsequent degradation of [125I]AGE-
BSA, which were inhibited e¡ectively by the anti-CD36 anti-
body. Ligand speci¢city of CD36 for modi¢ed BSAs was com-
pared with that of LOX-1 and scavenger receptor class A. Ef-
fect of fucoidan on [125I]AGE-BSA binding showed a sharp
contrast to that on [125I]-oxidized low density lipoprotein. These
results implicate that CD36-mediated interaction of AGE-modi-
¢ed proteins with adipocytes might play a pathological role in
obesity or insulin-resistance.
6 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
In the Maillard reaction, incubation of proteins with glu-
cose leads, through the formation of early products such as
Schi¡ base and Amadori products, to formation of advanced
glycation end products (AGE) [1]. During AGE formation,
several aldehydes such as 3-deoxyglucosone [2], glycolalde-
hyde (GA) [3], glyoxal (GO) [3] and methylglyoxal (MG) [2]
are generated as intermediates and react mainly with lysine
and arginine residues of proteins. Through modi¢cation of
these basic amino acids, proteins decrease positive charges
and increase their net negative charges [3]. AGE proteins
are characterized physicochemically by £uorescence, brown-
ing, molecular cross-linking [1].
Accumulation of AGE in human tissues is thought to in-
crease with aging and age-related disorders such as diabetic
complications and atherosclerosis [4^7]. Cellular interactions
with AGE proteins are known to induce several biological
responses, not only endocytic uptake and degradation, but
also induction of cytokines and growth factors, which linked
to the development of diabetic vascular complications [8].
These responses are thought to be mediated by AGE receptors
such as the receptor for AGE [9], a complex of OST-48/80K-
H/galectin-3 [10,11], class A scavenger receptor (SR-A)
[12,13], class B scavenger receptor (CD36 [14] and SR-BI
[15]), and LOX-1 [16].
Recent studies revealed that adipose tissues are biologically
active and dynamic, and play important endocrine and possi-
bly immunological functions in vivo [17^22]. Our recent study
using 3T3-L1-derived adipocytes demonstrated that oxidized
low density lipoprotein (OxLDL) is endocytosed by these cells
via CD36 [23]. Our previous study using Chinese hamster
ovary (CHO) cells overexpressing human CD36 also suggests
that CD36 serves as an AGE receptor [14]. Combined these
results together, it seems reasonable to expect that AGE pro-
teins are recognized and underwent endocytic degradation by
adipocytes via CD36.
The present study using mouse 3T3-L1 and human subcu-
taneous adipocytes has demonstrated that this is the case,
suggesting a potential role of AGE proteins in vivo in regu-
lation of adipocyte functions via CD36.
2. Materials and methods
2.1. Materials
Na[125I] (3.7 GBq/ml) was purchased from Amersham Pharmacia
Biotech (Buckinghamshire, UK). Mouse anti-murine CD36 monoclo-
nal antibody (clone 63) and anti-human CD36 antibody (FA6.152)
were purchased from Cascade Bioscience (Winchester, MA, USA) and
Immunotech (Luminy, France), respectively. Mouse IgA U (TEPC 15)
and IgG (MOPC21) were obtained from Sigma (St. Louis, MO,
USA). All other chemicals were of the analytical grade commercially
available.
2.2. Cell culture
Mouse 3T3-L1 cells (Health Science Research Resources Bank,
Osaka, Japan) were plated and grown in a basal medium (Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum (FCS), 20 U/ml penicillin, and 20 Wg/ml streptomycin). Cells
were then di¡erentiated by changing to a basal medium plus 10 Wg/ml
insulin, 0.25 WM dexamethasone (DEX), and 0.5 mM isobutylmethyl-
xanthine (IBMX). After 48 h, the medium was replaced with basal
medium containing 5 Wg/ml insulin, and cells were maintained in this
medium until use.
Human subcutaneous preadipocytes (Toyobo, Tokyo, Japan) were
di¡erentiated to adipocytes by changing to a DMEM/Ham’s F12
medium containing 1% FCS, 5 Wg/ml insulin, 10 Wg/ml transferrin,
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1 nM triiodo-L-thyronine, 0.25 WM DEX, and 0.5 mM IBMX, and the
adipocytes used for the cellular assays were at 10 days after di¡er-
entiation.
2.3. Preparation of AGE-bovine serum albumin (AGE-BSA),
aldehyde-modi¢ed proteins and lipoproteins
AGE-BSA was prepared as described previously [24]. Brie£y, 2.0 g
of BSA was incubated with 3.0 g of D-glucose in 10 ml of 0.5 M
sodium phosphate bu¡er (pH 7.4) for 40 weeks at 37‡C, and dialyzed
against phosphate-bu¡ered saline. The extent of lysine modi¢cation in
AGE-BSA was 75.7% of total lysine residues. MG-, GA-, and GO-
modi¢ed BSA were prepared as described previously [3]. AGE-BSA
was labeled with [125I] using Iodogen (Pierce Chemical Co.) to give a
speci¢c radioactivity of 450 cpm/ng [14]. LDL (d=1.019^1.063 g/ml),
OxLDL, and acetylated LDL (AcLDL) were prepared as described
previously [25].
2.4. Cellular assays
Binding, cell-association and degradation of [125I]AGE-BSA were
performed as described previously [14]. For the binding assay, cells
were incubated with 1.0^10 Wg/ml [125I]AGE-BSA at 4‡C in 1.0 ml of
DMEM containing 3% BSA for 1.5 h. Non-speci¢c binding was mea-
sured in the presence of a 20-fold excess of AGE-BSA and subtracted
from the data. For cell-association and degradation assays, cells were
incubated with 5 Wg/ml [125I]AGE-BSA at 37‡C in DMEM containing
3% BSA for 16 h. For inhibition assays, cells were incubated with or
without various compounds (100 Wg/ml) or antibodies (0.1^10 Wg/ml
of anti-CD36 antibody clone 63 or control IgA for 3T3-L1 cells and
10 Wg/ml of FA6.152 or control IgG for human adipocytes). Results
are represented as the meansRS.D. (n=3).
3. Results
3.1. Interaction of preadipocytes and adipocytes with
[125I]AGE-BSA
We ¢rst examined the interaction of 3T3-L1 cells with
[125I]AGE-BSA at 37‡C. The speci¢c cell-association markedly
increased after di¡erentiation to adipocytes at day 5 (Fig.
1A,B). The speci¢c cell-association of the adipocytes exhibited
a dose-dependent saturation pattern with a plateau at 1.6 Wg/
mg of cell protein and apparent Kd of 2.3 Wg/ml (Fig. 1B). The
cell-association was followed by subsequent endocytic degra-
dation. The speci¢c degradation of [125I]AGE-BSA by adipo-
cytes was similarly increased to reach a plateau at 300 ng/mg
of cell protein and apparent Kd of 1.5 Wg/ml (Fig. 1D). These
results indicate that adipocytes have the ability to endocytose
and degrade AGE proteins.
We next examined the cellular binding of [125I]AGE-BSA to
adipocytes at 4‡C. The total binding of [125I]AGE-BSA was
e¡ectively inhibited by excess amount of unlabeled AGE-
BSA. The speci¢c binding was saturable (Fig. 2) and Scatch-
Fig. 1. Endocytic uptake and degradation of [125I]AGE-BSA by 3T3-L1 adipocytes. 3T3-L1 cells of preadipocytes (day 0, panels A and C) and
adipocytes (day 5, panels B and D) were incubated at 37‡C for 16 h with various concentrations of [125I]AGE-BSA in the presence (open
square) or absence (open circle) of an excess of unlabeled AGE. Amounts of cell-associated [125I]AGE-BSA (A,B) and those of degraded (C,D)
were determined as described in Section 2. Speci¢c cell-association and degradation (¢lled circle) were plotted after correcting for non-speci¢c
cell-association and degradation. Values are meansRS.D. (n=3).
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ard analysis (Fig. 2, inset) revealed a single binding site with
an apparent Kd of 7.3 Wg/ml and maximal surface binding of
893 ng/mg of cell protein, indicating that di¡erentiated 3T3-
L1 adipocytes possess a high a⁄nity binding site for
[125I]AGE-BSA. This Kd value of these adipocytes is the
same order of magnitude with that of CD36-CHO cells (5.6
Wg/ml) [14].
3.2. Anti-murine CD36 monoclonal antibody inhibits endocytic
uptake of [125I]AGE-BSA by adipocytes
To assess the relative contribution of CD36 to cellular bind-
ing and endocytic degradation of [125I]AGE-BSA by 3T3-L1
adipocytes, we examined the e¡ects of the anti-CD36 antibody
on these phenomena. The cellular binding of [125I]AGE-BSA
was inhibited by the antibody in a dose-dependent manner
and the inhibition level reached 80% of controls (Fig. 3A).
Endocytic degradation was almost completely inhibited by
the antibody (Fig. 3B), whereas non-immune IgA used as a
control had no e¡ect on the cellular binding and endocytic
degradation. These results indicate that CD36 plays a major
role in both cellular binding of AGE-BSA to and subsequent
endocytic degradation by 3T3-L1 adipocytes.
Fig. 2. Cellular binding of [125I]AGE-BSA to 3T3-L1 adipocytes. 3T3-L1 adipocytes (day 5) were incubated at 4‡C for 90 min with various
concentrations of [125I]AGE-BSA in the presence (open square) or absence (open circle) of excess unlabeled AGE-BSA. Speci¢c binding (¢lled
circle) was determined by subtracting non-speci¢c binding from total binding. Inset: Scatchard analysis of the speci¢c binding curve. B/F is
bound/free.
Fig. 3. E¡ects of anti-CD36 antibody on cellular binding of [125I]AGE-BSA to and endocytic degradation by 3T3-L1 cells. 3T3-L1 adipocytes
(day 8) were incubated with [125I]AGE-BSA (5 Wg/ml) at 4‡C for 90 min (for binding experiments) or 37‡C for 16 h (for degradation experi-
ments) in the absence or presence of increased concentrations of the antibody (¢lled circle) or control IgA (open circle). The amounts of cell-
bound [125I]AGE-BSA (A) and those degraded by these cells (B) were determined. The values for speci¢c 100% binding and degradation were
203 and 408 ng/mg of cell protein, respectively.
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3.3. E¡ects of AGE ligands and modi¢ed LDLs on the
cell-association with and endocytic degradation of
[125I]AGE-BSA by 3T3-L1 adipocytes
To determine the ligand speci¢city of a receptor recognizing
AGE-BSA in di¡erentiated 3T3-L1 cells, several compounds
were examined for their e¡ects on the binding and endocytic
degradation of [125I]AGE-BSA by the adipocytes. The binding
of [125I]AGE-BSA was e¡ectively (s 70%) inhibited by
OxLDL, AcLDL, and unlabeled AGE-BSA (Fig. 4A). These
ligands also inhibited e¡ectively the degradation of [125I]AGE-
BSA by adipocytes (Fig. 4B). By contrast, LDL had no e¡ect
on the binding and degradation (Fig. 4A,B). Fucoidan, a pol-
yanionic inhibitor for SR-A [26] inhibited the cellular binding
and endocytic degradation of [125I]AGE-BSA (85% and 50%,
respectively). This ¢nding is in contrast with our previous
result that polyanionic compounds had no inhibitory e¡ect
on the endocytic uptake of OxLDL by di¡erentiated 3T3-L1
cells [23].
Since it is generally accepted that several aldehydes such as
3-deoxyglucosone, GA, GO and MG [2,3] are generated as
intermediates during the Maillard reaction and contribute to
formation of AGE structures, we also examined whether BSA
modi¢ed by aldehydes could serve as ligands for adipocytes.
GA-BSA and MG-BSA inhibited the [125I]AGE-BSA binding
to adipocytes by 70%, whereas GO-BSA had no inhibitory
e¡ect on it (Fig. 4A). Although the extent of inhibition was
somewhat weaker, inhibition patterns of these ligands for en-
docytic degradation of [125I]AGE-BSA were similar to those
of binding (Fig. 4B).
3.4. Human subcutaneous adipocytes recognize and degrade
[125I]AGE-BSA via CD36
We also examined the cellular interaction and response of
human subcutaneous adipocytes with [125I]AGE-BSA. The
speci¢c cell-association and degradation markedly increased
after di¡erentiation to adipocytes (Fig. 5A,B). In addition,
binding and endocytic degradation were almost completely
inhibited by excess of AGE-BSA and GA-BSA. OxLDL in-
hibited the binding and endocytic degradation, while LDL
had no e¡ects. Anti-human CD36 antibody FA6.152 com-
pletely inhibited these activities (Fig. 5C,D). These results
clearly indicate that CD36 plays a major role in both cellular
binding of AGE-BSA to and subsequent endocytic degrada-
tion by human adipocytes as well.
4. Discussion
The present study has clari¢ed that AGE proteins are rec-
ognized by 3T3-L1 and human subcutaneous primary adipo-
cytes, and undergo e¡ectively endocytic degradation by these
cells. The anti-CD36 antibody inhibited s 80% of the speci¢c
binding and s 95% of the speci¢c degradation of AGE-BSA
Fig. 4. E¡ects of several ligands on binding of [125I]AGE-BSA to and endocytic degradation by 3T3-L1 adipocytes. 3T3-L1 adipocytes (day 8)
were incubated at 4‡C for 90 min or 37‡C for 16 h with [125I]AGE-BSA (5 Wg/ml) in the presence or absence of 100 Wg/ml test compounds,
and the amounts of cell-bound [125I]AGE-BSA (A), and those degraded by the cells (B) were determined. The values for 100% binding and deg-
radation were 220 and 430 ng/mg of cell protein, respectively. Values are meansRS.D. (n=3).
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by these cells. It is highly likely, therefore, that CD36 plays a
major role in interaction of AGE-ligands with adipocytes.
Our previously study using CD36-overexpressed CHO cells
clari¢ed that CD36 serves as an AGE receptor [14]. The
present study provides a novel information that adipocytes
also take up and degrade AGE ligands via CD36. MG-BSA
and GA-BSA but not GO-BSA exhibited ligands as e¡ective
as AGE-BSA did. This ligand speci¢city is similar to that of
LOX-1 [16], but di¡erent from that of SR-A [3]. NO -(carboxy-
methyl) lysine (CML) contents were high in GO-BSA, but low
in glucose-derived, GA-, and MG-BSA [3]. It is likely that
the CML structure does not serve as a signal for the CD36
receptor recognition. Cellular uptake and degradation of
[125I]AGE-BSA were inhibited by OxLDL. Polyanionic com-
pound fucoidan inhibited e¡ectively the cellular binding of
AGE-BSA to 3T3-L1 adipocytes (Fig. 4A). The latter ¢nding,
however, is a sharp contrast to our previous observation that
the fucoidan had no e¡ect on [125I]OxLDL binding to 3T3-L1
adipocytes [23]. These results suggest that the binding domain
of CD36 for AGE ligands shares with that for OxLDL, but
the two binding domains are not identical with the respect of
fucoidan binding site. If substantial amount of AGE-BSA and
OxLDL coexist in vivo, these results suggest that the potential
competition of both ligands may inhibit their clearance by
endocytic uptake and degradation in adipocyte to increase
the severity and risk of AGE-induced diabetic complications
and/or atherogenesis, as discussed later.
Adipose tissues are currently thought to be a biologically
active and dynamic tissue playing a major endocrine and pos-
sibly immunological role [17^22]. In the present study, we
showed that adipocytes endocytosed and lysosomally de-
graded AGE-BSA. This phenomenon could be potentially re-
lated to pathophysiological functions of adipocytes.
In vivo signi¢cance of AGE has mainly been examined
from the AGE structure(s) expressed in vivo and AGE recep-
tors, through which AGE proteins are believed to elicit several
biological phenomena in monocytes/macrophages [27,28], en-
dothelial cells [29] and mesangial cells [30]. In macrophages,
Fig. 5. Endocytic uptake and degradation of [125I]AGE-BSA by human subcutaneous adipocytes. Human subcutaneous preadipocytes (open
circle) and adipocytes (¢lled circle) were incubated at 37‡C for 16 h with various concentrations of [125I]AGE-BSA in the presence or absence
of excess amount of unlabeled AGE. Speci¢c amounts of cell-associated [125I]AGE-BSA (A) and those of the degraded (B) were plotted after
subtracting non-speci¢c cell-association and degradation. Adipocytes were incubated at 4‡C for 90 min or 37‡C for 16 h with [125I]AGE-BSA
(5 Wg/ml) in the presence or absence of 100 Wg/ml test compounds and 10 Wg/ml antibodies, and then the amounts of cell-bound [125I]AGE-
BSA (C), and those degraded by the cells (D) were determined. The values for speci¢c 100% binding and degradation were 170 and 180 ng/mg
of cell protein, respectively. Values are meansRS.D. (n=3).
FEBS 26992 13-2-03
A. Kuniyasu et al./FEBS Letters 537 (2003) 85^90 89
AGE proteins stimulate the production of cytokines such as
tumor necrosis factor (TNF)-K [28], and up-regulate the ex-
pression of scavenger receptors through activation of perox-
isome proliferator-activated receptor-Q (PPAR-Q) [31]. Adipo-
cytes secrete various cytokines, including TNF-K [19], resistin
[20] and plasminogen activator inhibitor-1 [21], which are
closely associated with occurrence of insulin-resistance and/
or atherosclerosis. PPAR-Q also regulates the metabolism of
lipid and glucose [32]. Therefore, it would be an interesting
issue to determine whether AGE ligands could stimulate the
cytokine production and lipid accumulation in adipocytes in
vitro, and elucidate the correlation between the plasma level
of AGE proteins and adipocyte-derived cytokines in vivo.
Although paradoxical, the opposite way of interpretation of
the present results could be that the endocytic activity of
adipocytes for AGE-proteins and OxLDL [23] may relate to
the clearance of these oxidative stress-induced denatured pro-
teins from the circulation. There is accumulating evidence that
plasma levels of AGE proteins positively correlate with the
severity of diabetic complications and cardiovascular diseases
[8]. Hepatic sinusoidal cells such as endothelial cells and
Kup¡er cells have been shown to serve as one of the major
clearance sites for plasma AGE-BSA [33] and OxLDL [34]. It
is possible therefore that CD36-mediated phagocytosis of
AGE-BSA by adipocytes could be a physiological mechanism
for reducing the severity and risk of AGE-induced diabetic
complications and/or atherogenesis.
In summary, the present study demonstrated that CD36 is a
key player in active endocytic uptakes by 3T3-L1 and human
subcutaneous adipocytes of AGE ligands such as AGE pro-
teins and proteins modi¢ed by GA and MG. There has been
no report on a functional link between AGE accumulation in
adipocytes and the pathogenesis of diabetes or diabetic com-
plications. Our present study may provide insights into a po-
tential role of AGE proteins in regulation of adipocyte func-
tions via CD36. Further studies are required to determine
what amount of AGE proteins taken up by adipocytes
through CD36 could contribute to AGE-induced pathological
states such as diabetic complications and atherosclerosis.
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